Q2 revenue up 111%, profit at Rs 11.8 Cr and EBITDA margin 17.3%
BPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 FY27 revenue rose 110.9% year on year to Rs 136.28 Cr. EBITDA was Rs 23.58 Cr at a 17.3% margin versus 1.3% a year ago, and net profit was Rs 11.82 Cr against a loss of Rs 8.60 Cr. Half-year revenue grew 27.4% to Rs 230.02 Cr, with operating cash flow of Rs 83.33 Cr. Standalone Q2 profit nearly doubled to Rs 5.42 Cr. Innoxel turned profitable and began US commercial supply.
Strong growth, wider margins and a return to profit should support sentiment, though input cost inflation and minority losses are risks.